Figure 4.

Epitope mapping of SARS-CoV-2 infectivity-enhancing antibodies

(A) Binding of enhancing antibodies (binder) to full-length spike transfectants was analyzed in the presence of the indicated antibodies (competitor). The effect of competitors on ACE2-Fc binding to the spike transfectants was also analyzed. The non-enhancing anti-S2 antibody, COV2-2147, was used as a control. Relative antibody- or ACE2-binding levels observed in the presence of competitor are shown.

(B) Relative antibody-binding levels to a series of NTD mutants compared to wild-type NTD are shown. Non-enhancing anti-NTD antibody 4A8 was used as a control. The most affected residues are shown as red.

(C) Full-length mutant spike proteins were stained with the indicated enhancing antibodies (red line). Staining of wild-type spike is shown as a shaded histogram.

See also Figure S3.